Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for ...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops ...
Over the past few months, ADMA Biologics ( ADMA ) has been able to record several key accomplishments and milestones. During the second quarter, the company received FDA approval for both BIVIGAM and ASCENIV. In addition, the company now has product licenses for Nabi-HB and BIVIGAM. What is mo...
ADMA Biologics (NASDAQ: ADMA ) announces the commercial relaunch and its first commercial sales of BIVIGAM. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three appro...
ADMA Biologics (NASDAQ: ADMA ): Q2 GAAP EPS of -$0.25 beats by $0.04 . More news on: ADMA Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...